Moderna Will Launch Large Combination Vaccine Trial
The upcoming DAN-COMBO study will assess mRNA-1083 effectiveness in 410,000 older adults across Europe.
Updated on Oct. 3, 2026 in COVID-19
Live Poll
Should clinical vaccine trials always require placebo groups and participant blinding for safety and accuracy?
Moderna is planning the DAN-COMBO clinical trial to evaluate its mRNA-1083 combination vaccine in 410,000 adults aged 65 and older. The study is scheduled to occur in Denmark and Spain during the next cold-and-flu season.
Why it matters
The trial aims to provide comparative evidence on the effectiveness of combined versus separate COVID-19 and flu vaccinations. This research seeks to address existing data gaps surrounding the dual-vaccine approach.
The study targets 410,000 participants aged 65 and older to compare mRNA-1083 against separate Spikevax and mRNA-1010 injections. While mRNA-1083 is approved for those aged 50 and older in Europe, its U.S. application remains withdrawn.
The players
Moderna
A biotechnology company specializing in messenger RNA therapeutics and vaccine development.
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
European Medicines Agency
The European Union agency responsible for the evaluation and supervision of pharmaceutical products.
The details
The trial design has faced scrutiny from scientists and physicians regarding its methodology and safety protocols, notably because it lacks a placebo group and does not use blinding. Researchers are comparing the combination vaccine against the standard mRNA-1010 flu vaccine and Spikevax COVID-19 vaccine.
Timeline
The DAN-COMBO trial is scheduled for the next cold-and-flu season.
The FDA initially declined to review the mRNA-1010 application in February 2026.
The Big Picture
This research follows a complex regulatory history regarding the mRNA-1010 vaccine, which saw initial rejection by the FDA before later acceptance. The study marks a significant attempt to build a broader evidence base for combination vaccines following the withdrawal of the U.S. application for mRNA-1083.
Patients aged 65 and older may eventually see new vaccination options if the study validates the combination approach. The absence of a placebo group in this trial design may influence how future clinical data is interpreted by medical providers.
The takeaway
The DAN-COMBO trial represents a major push to standardize combined immunization, though its unique study design remains a point of contention among experts. Participants and healthcare providers should monitor future peer-reviewed findings to understand how these results might shift standard vaccination guidelines.
Further reading
For more information on vaccine research, visit the COVID-19 section.
Source note: This article includes information reported by National Daily NG.
Live Poll
Should clinical vaccine trials always require placebo groups and participant blinding for safety and accuracy?
